Prof. Hartmut J Ehrlich, M.D., Chief Executive Officer
Hartmut is a physician with 30 years in academia and in the biopharmaceutical industry, 20 of which were in product development at Baxter and Sandoz (now Novartis). He has lived and worked in the United States (Eli Lilly and Indiana University, Dept. of Medicine), the Netherlands (Central Laboratory of the Dutch Red Cross), Germany (Max Planck Foundation, Sandoz, Baxter), Switzerland (Sandoz), Austria (Baxter) and France (ABIVAX). Over the past 7 years before joining ABIVAX, Hartmut successfully built and advanced Baxter BioScience’s R&D portfolio with over 50 programs in preclinical and clinical development. He drove the regulatory approval of key biologics in the specialty areas of Hemophilia, Thrombosis, Immunology, Neurology, Oncology, BioSurgery and Vaccines, thereby bringing novel therapies to patients with substantial medical needs. Hartmut has authored and co-authored over 120 peer-reviewed articles and book chapters. In 2011, Hartmut was named “Professor” by the Austrian President and the Austrian Minister for Science and Research, and he received the title of “Adjunct Professor” of the Danube University Krems, Lower Austria in 2013.
Didier Blondel, Chief Financial Officer and Board Secretary
Didier was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon-based joint-venture between Sanofi and Merck, and European leader in human vaccines, since 2012. During the previous 20 year period, Mr. Blondel held a wide scope of senior finance positions at Sanofi, in Commercial Operations and then R&D, where he became Global R&D CFO. Didier Blondel started his career as an auditor at Price Waterhouse Coopers, after graduating from the Commercial Institute of Nancy (ICN), a leading French Business School. He also holds a Master in Finance and Accounting degree from University of Nancy, as well as a Professional Certificate in Finance and Accounting (DESCF).
Pierre Courteille, Chief Commercial Officer & Vice President Business Development
Pierre has more than 20 years experience in marketing and sales within the pharmaceutical industry in France and in Japan, where he has worked for 13 years. He holds a pharmacy degree and MBA from Chicago Booth University (USA). At Sanofi-Pasteur Japan, and its joint-venture with Daiichi, Pierre Courteille was in charge of the pre-launch activities of HIB/ meningitis and IPV/polio vaccines as Marketing Manager. At the start of 2005, he became President of Guerbet Japan and VP for Guerbet Asia. He successfully managed the roll-out of its Japanese subsidiary and led the development of other branches in Asia. From 2009, Pierre served as VP Sales for Asia, Latin America and EMEA and met the ambitious objective of optimizing commercial performance across these 3 regions. Prior to joining ABIVAX, Pierre was Senior VP sales and marketing for Guerbet and CEO of MEDEX (medical devices company owned by Guerbet) from 2012.
Bernard Fanget, Vice President Process Development, Manufacturing and Regulatory Affairs
Bernard has more than 30 years of industrial experience in the development of vaccines and recombinant proteins. Since 2005 he has held the position of Vice President of Pharmaceutical Affairs in Neovacs. He was previously Senior Vice President in charge of pharmaceutical development at Flamel Technologies, and Corporate Vice President, Global Industrialization division at Sanofi Pasteur. Bernard has developed several technologies to large-scale production and has registered many vaccines. Bernard is a member of several working groups within the World Health Organization. He graduated in Biochemistry from the University of Lyon, France.
Didier Scherrer, Ph.D., Vice President R&D
Didier, prior to joining ABIVAX, combined the functions of CEO and Scientific Directory at Splicos. Didier has a PhD in Molecular Pharmacology. He completed his post-doctoral studies at Harvard Medical School and then at the Stanford University School of Medicine. Research Director at Entelos (California – USA) from 2000 to 2005, he then joined the Research Department of Astra-Zeneca as Associate Director (Capability Pathways – Discovery Enabling Capabilities and Sciences), and then as Head of Research, at LFB Biotechnologies where he led a team of fifty scientists in charge of developing the portfolio of therapeutic proteins in oncology, autoimmune diseases and hematology-oncology. He is the author of numerous publications and presentations in the field of systems biology applied to the research and drug development.
Jean-Marc Steens, M.D., Chief Medical Officer
Jean-Marc is a physician and has 30 years of experience in the biopharmaceutical industry. After completing his medical education, he obtained a post-doctoral degree in Public Health at the Catholic University of Louvain (Belgium). He began his career at Sandoz in Belgium and subsequently joined Glaxo where he remained for more than 20 years and had extensive responsibility, in Europe and in the United-States, for the global clinical development, medical affairs and access programs for novel therapies and vaccines to treat HIV and other infectious diseases. In 2009, Dr. Steens was appointed Vice President and International Medical Director of ViiV Healthcare, with the mission to establish and manage medical departments across Eastern Europe, Asia and Latin America. Since 2013, Dr. Steens has consulted to various Biopharmaceutical companies, including Novartis. Dr. Steens is a member of the HIV advisory boards and steering committees of several global and national healthcare organizations such as the WHO and the National Institutes of Health (US).
Paul Gineste, VP Clinical Operations
Paul brings 20 years of experience in clinical development and strategy with leading international pharmaceutical and biotech companies. Paul began his career in 1998 with Boehringer Ingelheim as International Clinical Trials Manager before taking over, in 2003, the position of Head of Clinical R&D at Altana Pharma. In 2007, Paul was appointed Director of Clinical Studies at AB Science where he led the early clinical development of a tyrosine kinase inhibitor in the U.S. and Europe. In 2013, he moved to Theravectys, a spin-off of the Institut Pasteur specialized in lentiviral vectors, as Executive VP, Clinical Development. Paul joined ABIVAX in 2015 as Head of Clinical Operations. Paul holds a doctorate in pharmacy from the University of Rouen, France and a Master’s degree in Law from the University of Paris XI.
Jamal Tazi is professor of functional genomics at the University of Montpellier, Senior Member at the University Institute of France and deputy director of the health center biology " Rabelais" responsible for education and training. After a thesis on molecular and cellular biology defended in 1988, he performed a postdoctoral fellow at the Institute of Pathology Molcular (Austria), before joining the CNRS in 1990. For 20 years , he led the team " messenger RNA metabolism in metazoans " within the Institute for Molecular Genetics in Montpellier ( IGMM ) to gain a better understanding of the fundamental mechanisms of the expression of our genes and editing of their products. To ensure the transition between basic and applied research, and also to support these innovative projects to the clinical stage, in 2008 Jamal founded the company Splicos and established its partnership with public institutions as a cooperative laboratory, where he became Scientific Director. Jamal has co-authored over 90 publications in some of the leading international journals: Nature, Nature Cell Biology , Science, Cell, PNAS , EMBO J. His Work on RNA metabolism and its role in human disease allowed him to win three prizes; by the French Academy of Sciences in 1999, the French Academy of Medicine in 2006, in 2010 ARRI and in 2017 Médaille de l'innovation of CNRS. Internationally, Jamal is the coordinator of an European Associated Laboratory (LEA) and also a member of a European network of excellence (EURASNET) which brings together the best European research centers working on alternative splicing.